Related-Party Transactions |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Related Party Transactions [Abstract] | |
| Related-Party Transactions | 11. Related‑party transactions During the three and six months ended June 30, 2026, the Company received scientific advisory and consulting services from one of its prior executives, Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three months ended June 30, 2026 and 2025 was $0.2 million and $0.1 million, respectively. The total amount of fees paid to Dr. Sah for services provided during each of the six months ended June 30, 2026 and 2025 was $0.3 million. Under both the 2019 Neurocrine Collaboration Agreement and the 2023 Neurocrine Collaboration Agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization activities for certain of the Company’s AAV gene therapy product candidates. Any amounts due from Neurocrine are reflected as related party collaboration receivable. Amounts received from Neurocrine that have not yet been recognized as revenue are reflected as deferred revenue. Refer to Note 8 for further description of these account balances. For the three months ended June 30, 2026 and 2025, the Company recognized collaboration revenue of $0.4 million and $3.7 million, respectively, related to the 2023 and 2019 Neurocrine Collaboration Agreements. For the six months ended June 30, 2026 and 2025, the Company recognized collaboration revenue of $1.8 million and $8.6 million, respectively, related to the 2023 and 2019 Neurocrine Collaboration Agreements. |